Compare · FDMT vs RGNX
FDMT vs RGNX
Side-by-side comparison of 4D Molecular Therapeutics Inc. (FDMT) and REGENXBIO Inc. (RGNX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FDMT and RGNX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- FDMT is the larger of the two at $608.3M, about 1.3x RGNX ($478.7M).
- RGNX has been more active in the news (10 items in the past 4 weeks vs 7 for FDMT).
- RGNX has more recent analyst coverage (24 ratings vs 20 for FDMT).
- Company
- 4D Molecular Therapeutics Inc.
- REGENXBIO Inc.
- Price
- -
- -
- Market cap
- $608.3M
- $478.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2015
- News (4w)
- 7
- 10
- Recent ratings
- 20
- 24
4D Molecular Therapeutics Inc.
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; Benitec; CRF; Roche; CFF; and AstraZeneca. The company was founded in 2013 and is headquartered in Emeryville, California.
REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Latest FDMT
- Amendment: SEC Form SCHEDULE 13G/A filed by 4D Molecular Therapeutics Inc.
- 4DMT Announces New Employment Inducement Grants
- SEC Form 10-Q filed by 4D Molecular Therapeutics Inc.
- 4D Molecular Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- 4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
- SEC Form SCHEDULE 13G filed by 4D Molecular Therapeutics Inc.
- 4DMT to Participate in Upcoming Investor Conferences
- Chief Legal Officer Bizily Scott sold $20,993 worth of shares (1,635 units at $12.84) as part of a pre-agreed trading plan (SEC Form 4)
- 4DMT Announces New Employment Inducement Grants
- Officer Kirn David sold $753,937 worth of shares (58,333 units at $12.92) as part of a pre-agreed trading plan (SEC Form 4)
Latest RGNX
- SEC Form SCHEDULE 13G filed by REGENXBIO Inc.
- SEC Form 10-Q filed by REGENXBIO Inc.
- REGENXBIO Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights
- Chief Technology Officer Malzahn Craig was granted 27,777 shares, increasing direct ownership by 34% to 109,737 units (SEC Form 4)
- Chief Strategy & Legal Officer Christmas Patrick J. was granted 34,722 shares, increasing direct ownership by 17% to 240,690 units (SEC Form 4)
- Chief Medical Officer Pakola Steve was granted 34,722 shares, increasing direct ownership by 17% to 240,263 units (SEC Form 4)
- Chief Financial Officer Chan Mitchell was granted 24,305 shares, increasing direct ownership by 20% to 147,120 units (SEC Form 4)
- REGENXBIO to Participate in Stifel 2026 Healthcare Conference
- REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights